| HS Code | 468376 |
| Product Name | Pharma Grade Methyl Cellulose (MC) |
| Product Type | Pharmaceutical grade API/excipient |
| Chemical Name | Methyl cellulose |
| Cas Number | 9004-67-5 |
| Molecular Formula | C6H7O2(OH)3-x(OCH3)x |
| Appearance | White to off-white, odorless, tasteless powder or granules |
| Solubility | Soluble in cold water; practically insoluble in hot water, ethanol, acetone, and chloroform |
| Viscosity | Available in various grades, e.g., 15 mPa·s to 100,000 mPa·s (2% aqueous solution at 20°C) |
| Ph | 5.5 to 8.0 (2% aqueous solution) |
| Methoxyl Content | 27.5% to 31.5% |
| Assay Purity | Pharmaceutical grade, compendial compliance |
| Functional Category | Coating agent, binder, thickener, suspending agent, controlled-release matrix former |
| Dosage Forms | Tablet, capsule, granule, injection |
| Route Of Administration | Oral, injectable |
| Sterility | Sterile and pyrogen-free for injectable grade; non-sterile for oral grades |
| Pharmacopoeia Compliance | USP/NF, EP, JP as applicable |
| Storage Conditions | Store in a dry, well-closed container at controlled room temperature |
| Shelf Life | Typically 24 to 36 months when stored properly |
| Packaging | Fiber drum, polyethylene-lined bag, or as per customer requirement |
As an accredited Pharma Grade Methyl Cellulose (MC) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Pharma-grade Methyl Cellulose supplied in 25 kg double-lined polyethylene fiber drums, sealed, suitable for tablets, capsules, granules, oral and injectable use. |
| Container Loading (20′ FCL) | 20′ FCL loaded with palletized pharma-grade methyl cellulose API drums, moisture-protected, secured for tablet, capsule, granule, oral, and injectable applications. |
| Shipping | Pharma Grade Methyl Cellulose (MC) API is shipped in sealed, tamper-evident, moisture-barrier, pharmaceutical-grade containers at controlled ambient temperature. Protect from light, moisture, heat, and contamination. Injectable grades require sterile, pyrogen-free packaging. Transport complies with GMP/GDP, IATA/DOT, and SDS requirements; labels include batch number, expiry, and handling instructions. |
| Storage | Store Pharma Grade Methyl Cellulose in a cool, dry, well-ventilated area at controlled room temperature, away from direct sunlight, heat, moisture, and incompatible materials. Keep containers tightly closed, upright, clean, and clearly labeled. Protect from humidity and contamination; maintain segregated, dedicated storage suitable for pharmaceutical APIs intended for oral and injectable use. Follow local regulations and manufacturer’s recommendations. |
| Shelf Life | Typically 24–36 months in unopened, tightly sealed containers stored cool, dry, protected from moisture, heat, and light; follow manufacturer’s retest date. |
Low-viscosity pharmacopoeial methylcellulose with nominal viscosity 5–7 mPa·s at 2% w/w and 20°C is hydrated in purified water at 10–15°C to a polymer concentration of 4.0–6.0% w/w; the resulting coating dispersion is applied to a 2.0–3.0% weight gain on tablet cores. Polyethylene glycol 400 is included as plasticizer at 10–20% w/w of polymer solids, and the dispersion is delivered through a 1.0 mm two-fluid nozzle at atomizing air pressure 1.5–2.5 bar and spray rate 40–60 g/min per nozzle. A 48-inch side-vented pan coater is operated with inlet air temperature 65–75°C, exhaust air temperature 40–45°C, and bed temperature maintained below the methylcellulose thermal gelation threshold of approximately 50°C. If bed temperature crosses that threshold, atomized droplets form gelled skins rather than coalescing films, producing orange-peel surface roughness, edge chipping, and dissolution lag time in USP <711> testing. Coated tablets are additionally assessed under USP <905> for mass uniformity and under USP <905> content uniformity where applicable. The terminal product is an immediate-release film-coated tablet intended for oral administration.
In controlled-release hydrophilic matrix systems, methylcellulose with nominal viscosity 4000 mPa·s at 2% w/w is dry-blended at 18–28% w/w with the active pharmaceutical ingredient and a water-soluble or water-insoluble filler such as lactose monohydrate or dibasic calcium phosphate dihydrate. Blending is performed in a bin blender at 10–14 rpm for 18–25 min; magnesium stearate is then added at 0.5–0.75% w/w and blended for an additional 2–4 min. Compression on a rotary tablet press with precompression force 4–8 kN and main compression force 12–20 kN produces a matrix core hardness of 80–120 N. The matrix hydrates on contact with dissolution fluid and forms a gel layer; drug release is evaluated in USP <711> Apparatus 2 at 50 rpm with 900 mL of pH 6.8 phosphate buffer, although media selection is drug-specific. The Korsmeyer-Peppas release exponent commonly falls between 0.45 and 0.89 for non-Fickian transport in similar cellulosic matrices, but published data for this specific methylcellulose configuration is limited. The terminal product is a monolithic sustained-release or controlled-release matrix tablet without wax or enteric coating.
Binder solution is prepared with methylcellulose 15 cP grade at 5–8% w/w in purified water at 8–15°C, using an axial turbine at 300–500 rpm; the solution is held for 60–90 min to eliminate microgel fisheyes. The dry-basis binder level is 2.0–4.0% w/w based on the granulation batch. Granulation is carried out in a bottom-driven high-shear mixer with impeller tip speed 4–6 m/s and chopper speed 1500–2000 rpm. The endpoint is controlled by impeller power draw rather than by fixed water volume: an increase of 30–50% above the dry-mix baseline corresponds to a wet mass consistency suitable for 0.8–1.2 mm granules. The wet mass is discharged, dried in a fluid-bed dryer with inlet air 60–65°C to loss on drying 1.5–2.5% w/w, and milled through a 0.8 mm Conidur screen. Granules are compressed into tablets or filled into hard capsules; dissolution and dose uniformity are tested under USP <711> and USP <905>, and residual moisture is determined by USP <731>. The terminal product types are immediate-release tablet cores and hard capsule granulate.
| Application segment | Primary pharmacopoeial/regulatory anchor | Specific test method or operational range |
|---|---|---|
| Aqueous tablet film coating | USP <711>, USP <905> | Coating weight gain 2.0–3.0% |
| Hydrophilic matrix tablet | USP <711> | Matrix polymer load 18–28% w/w |
| High-shear wet granulation | USP <711>, USP <905>, USP <731> | Loss on drying 1.5–2.5% w/w |
| Extrusion-spheronization pellet fill | USP <711>, USP <905> | Pellet diameter 0.85–1.25 mm |
| Oral suspension vehicle | USP <911>, USP <698> | Sedimentation volume after 24 h |
| Injectable suspension vehicle | USP <71>, USP <85>, USP <788> | Endotoxin limit per USP <85> |
Extrusion-spheronization of multiparticulate cores for hard capsule filling uses methylcellulose 50–100 cP grade at 2–5% w/w dry basis as the wet massing binder. The wet mass is extruded through a 0.8–1.0 mm screen at 20–40 rpm in a radial basket extruder, then spheronized at 600–900 rpm for 3–6 min to a median pellet diameter of 0.85–1.25 mm. The pellets are dried in a fluid-bed dryer with inlet air 60–65°C until moisture content reaches 1.0–2.0% w/w. Because spheronization can increase surface temperature, the process water and wet mass must remain below the methylcellulose thermal gelation boundary to avoid gelled binder skins that reduce sphericity and cause capsule fill weight drift. The finished pellets are filled into hard gelatin or HPMC capsules on a dosator or tamping pin filling machine; weight variation is verified under USP <905>, and drug release is tested under USP <711>. The terminal product is a pellet-filled hard capsule intended for oral administration.
High-viscosity methylcellulose 4000 cP grade is dispersed at 0.3–1.0% w/w in cold purified water at 8–15°C using an axial-turbine mixer. The polymer is preferably preblended with 10–20 parts of sucrose or mannitol per part methylcellulose before addition to water to prevent fisheye formation. Once fully hydrated, the solution develops pseudoplastic viscosity in the range of 200–800 mPa·s at 20°C and low-shear conditions. The dispersion is buffered to pH 3.5–6.5 before addition of preservative; high-salt buffers above 0.9% sodium chloride equivalent should be added after hydration because elevated ionic strength can reduce viscosity and shift sedimentation behavior. Viscosity is verified by USP <911> or Ph. Eur. 2.2.9 capillary viscometry, and deliverable volume is checked under USP <698>. The terminal product types are ready-to-use oral suspension and reconstitutable dry suspension for oral administration.
For non-intravenous parenteral suspensions, methylcellulose 400 cP grade is incorporated at 0.1–0.5% w/w in Water for Injection during cold aseptic compounding. The polymer is hydrated at 8–15°C with low-shear agitation to avoid air entrapment. Because methylcellulose solutions undergo reversible thermal gelation above approximately 50°C, terminal sterilization by autoclave at 121°C for 15 min must be followed by slow cooling under gentle agitation to restore a clear, particle-free solution; sterile filtration through 0.22 µm membranes is not generally feasible at the viscosity of the prepared vehicle. The solution is tested for sterility per USP <71>, bacterial endotoxins per USP <85>, and particulate matter per USP <788>. The pH is maintained between 5.0 and 7.0 where methylcellulose viscosity is stable under parenteral storage conditions. The route of administration is restricted to intramuscular or subcutaneous injection; published safety data for intravenous use of methylcellulose is limited. The terminal product is an aqueous injectable suspension or depot precursor containing micronized active pharmaceutical ingredient.
Competitive Pharma Grade Methyl Cellulose (MC) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8618963613625
Email: sales10@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Pharma Grade Methyl Cellulose (MC) Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is a white to off-white, odourless, free-flowing cellulose ether produced by controlled etherification of refined wood or cotton linter pulp with methyl chloride under alkaline conditions. The “API grade” designation refers to release against pharmaceutical impurity, microbial, and documentation requirements; in the finished dosage form methylcellulose is used as a non-ionic excipient and processing aid rather than an active pharmaceutical ingredient. Commercial model codes MC 15, MC 400, MC 1500, and MC 4000 identify nominal apparent viscosities of 15, 400, 1500, and 4000 mPa·s measured as a 2% w/w aqueous solution at 20 ± 0.1 °C using capillary viscometry per USP <911> or Ph Eur 2.2.9. The methoxy content is controlled to 27.5–31.5% on the dried basis, corresponding to a degree of substitution of approximately 1.6–2.0. The powder is cold-water-soluble and hot-water-insoluble, and it forms a pseudoplastic solution that undergoes thermoreversible gelation on heating.
In production-scale wet granulation, methylcellulose powder is not added directly to warm or hot aqueous binder solutions because hydration occurs only after particle wetting and gel-coated lumps can form around unhydrated cores. Low-viscosity grades such as MC 15 and MC 400 are dispersed in cold purified water at 1–5% w/w with a high-shear dispersion mixer or inline rotor-stator device until the solution clears, and free air is removed under vacuum. The binder solution is metered into a high-shear granulator or fluid-bed granulator at a dry-solids level of 1–3% w/w methylcellulose relative to the granulation mass. At this addition range the polymer increases granule cohesiveness, narrows dry-sieve particle-size distribution, and improves tablet hardness without functioning as a disintegrant. For capsule filling, the wet-granulation route produces free-flowing granules with a Hausner ratio below 1.25 and angle of repose below 35°, which support reproducible filling in auger and dosator-type capsule machines. Higher viscosity grades used above 3% w/w can extend disintegration time beyond 15 min in the compendial test of USP <701>.
Release documentation for the API-grade material includes a certificate of analysis with methoxy content, viscosity, loss on drying, residue on ignition, pH, microbial limits, and residual solvents. Injectable-grade lots add bacterial endotoxin testing per USP <85> and particulate matter control per USP <788>. Because methylcellulose is hygroscopic, containers are closed immediately after dispensing, and product stored above 60% relative humidity may require pre-drying before use in moisture-sensitive formulations. The dry powder is not a direct substitute for pregelatinized starch or copovidone in dry blending because its low bulk density and fibrous particle shape can reduce flow through the feed frame of a rotary tablet press if used above 10% w/w without granulation.
The limiting process variable during scale-up is not the static viscosity of the binder solution but the hydration rate and gel-blocking tendency of the polymer. Methylcellulose hydrates poorly above 40 °C and begins to form a gel network near 50–55 °C; therefore, warm water produces a dispersed particle slurry rather than a true solution. On production-scale equipment, the powder is sifted into a vigorously agitated cold-water vortex at 20–25 °C. Mixing is continued for 45–60 min for high-viscosity grades to reach complete clarity, and the solution is deaerated before use because entrained air bubbles can change spray-nozzle performance and tablet weight control.
For top-spray fluid-bed granulation, MC 400 and MC 1500 solutions above 5% w/w may be too viscous for standard peristaltic pump transfer and binary-nozzle atomization. Field experience in tablet manufacturing shows that 2–4% w/w solutions of MC 15 or MC 400 produce less nozzle blockage and foam than MC 4000; however, published data for specific equipment configurations is limited. The solution is pseudoplastic and shear-thinning, so its apparent viscosity drops under high shear, but recovery of viscosity during wet-mass hold time can vary with grade and temperature. The endpoint for high-shear granulation is therefore determined by impeller torque or power draw rather than by a fixed binder-addition time, because the power consumption increase from the dry-mix baseline is the most reproducible indicator of wet-mass saturation on a given machine.
The current USP-NF “Methylcellulose” monograph and the Ph Eur monograph specify methoxy content of 27.5–31.5% on the dried basis. Viscosity acceptance depends on the label claim: for labeled viscosities of 100 mPa·s or less, the measured value must be 80–120%; for label claims above 100 mPa·s, the measured value must be 75–140%. Loss on drying is limited to 5.0%, residue on ignition to 1.5%, and the pH of a 1% w/w aqueous preparation is controlled to 5.0–8.0. The supplier model code does not override these monograph limits; it is a commercial nomenclature for nominal viscosity. Table 1 summarizes the release specification for oral and injectable supply, with the injectable grade adding endotoxin and particulate controls.
| Attribute | Acceptance Limit / Nominal Value | Analytical Reference |
|---|---|---|
| Appearance | White to off-white, odourless powder | USP-NF “Methylcellulose” monograph |
| Methoxy content, dried basis | 27.5–31.5% | USP-NF “Methylcellulose” monograph |
| Apparent viscosity, 2% w/w, 20 ± 0.1 °C | Nominal grades 15, 400, 1500, 4000 mPa·s; 80–120% for ≤100 mPa·s, 75–140% for >100 mPa·s | USP <911>; Ph Eur 2.2.9 |
| Loss on drying | ≤5.0% | USP <731> |
| Residue on ignition | ≤1.5% | USP <281> |
| pH of 1% w/w aqueous preparation | 5.0–8.0 | USP <791> |
| Bacterial endotoxins, injectable grade | Limit assigned by intended dose and route | USP <85> |
| Particulate matter, injectable solution | Subvisible particle limits | USP <788> |
Compared with other cellulose ethers, methylcellulose differs primarily in substitution chemistry and gelation threshold. Hypromellose (HPMC) contains both methoxy and hydroxypropoxy substituents; its 2% w/w aqueous solutions typically gel between 75 °C and 90 °C depending on substitution type, whereas MC gels at approximately 50–55 °C. This difference makes HPMC more tolerant of heated processing, such as vacuum deaeration in coating pans, but MC provides a lower-temperature gel barrier that can be used in sustained-release matrix tablets. Sodium carboxymethylcellulose is anionic and may lose viscosity at pH below 2 or in the presence of polyvalent cations, while MC is non-ionic and remains compatible with many dissolved salts. Gelatin is animal-derived and exhibits a melt transition near 30–35 °C; MC is plant-derived, does not require cold storage, and does not undergo aldehyde-mediated crosslinking. Table 2 provides a comparative profile for materials commonly considered for the same dosage-form roles.
| Material | Ionic Character / Solubility | Thermal Gelation / Melt Transition | Practical Difference from MC |
|---|---|---|---|
| Methylcellulose (MC) | Non-ionic; cold-water-soluble | Thermoreversible gel at approx. 50–55 °C | Reference for tablet/capsule/granule binder and suspending agent |
| Hypromellose (HPMC) | Non-ionic; cold-water-soluble | Gelation approx. 75–90 °C by substitution type | Higher hot-processing tolerance; less useful for low-temperature gel barrier |
| Carmellose sodium (CMC-Na) | Anionic; water-soluble | No thermal gelation | Viscosity loss at pH <2 and with multivalent cations |
| Gelatin | Amphoteric; hot-water-soluble | Melt transition approx. 30–35 °C | Animal-derived; aldehyde crosslinking risk; thermoreversible by gel-sol melting |
Thermal gelation is the main operational boundary for oral liquids, injectable preparations, and granulating media. A 2% w/w solution of MC 4000 is a flowable liquid at 20 °C; on heating to 50–55 °C it forms a turbid, semisolid gel that reverts to a liquid on cooling below this range. This thermoreversible property is useful for suspending insoluble actives and modifying oral liquid rheology, but it creates a risk during steam sterilization because the gel phase can retain air bubbles, increase internal pressure, and produce non-uniform viscosity after cooling. Steam sterilization at 121 °C for 15 min of methylcellulose solutions therefore requires formulation-specific validation. If autoclaving cannot be qualified without gel-phase defects, aseptic filtration through a 0.22 µm membrane at 20–25 °C may be used, provided the solution viscosity is low enough for practical filter throughput. Published data for injectable methylcellulose solutions is limited, and each formulation must be qualified by viscosity recovery, pH, and subvisible particle testing under USP <788>.
In oral suspensions and granulating media, the processing limit is similar: do not prepare stock solutions in water above 40 °C, and do not add dry MC to a warm vortex. High-ionic-strength formulations should be checked for depression of gelation temperature, because certain salts reduce the temperature at which the gel network forms. The powder will not hydrate in hot water, and strongly alkaline or oxidizing media may degrade the cellulose ether chain unless compatibility data are available. These operational boundaries define the practical difference between methylcellulose and higher-gelling HPMC grades when hot-process tolerance is the critical parameter.